NQMC Update Service: June 15, 2015 ► Oncology Nursing Society

NQMC Update Service: June 15, 2015

Oncology Nursing Society

Oncology Nursing Society

• Breast cancer: percentage of cycles where patients who are prescribed a potentially myelosuppressive chemotherapy regimen receive a prescription for colony-stimulating factor (CSF) to begin within 24 to 72 hours after chemotherapy administration.

• Breast cancer: percentage of patients who had documentation of follow-up care (recommendations) during the 12-month period after completing the final component of the treatment plan for breast imaging, coordination of care, LVEF assessment, and pelvic exam.

• Breast cancer: percentage of patients who had moderate or greater fatigue at baseline (end of treatment) and had improvement in fatigue from baseline to most recent visit in chart during the 12-month period after completing the final component of the treatment plan.

• Breast cancer: percentage of patients who had moderate or greater psychosocial distress at baseline (end of treatment) and had improvement in psychosocial distress from baseline to most recent visit in chart during the 12-month period after completing the final component of the treatment plan.

• Breast cancer: percentage of patients who made progress toward goals by the end of the 12-month period after completing the final component of the treatment plan.

• Breast cancer: percentage of patients who received a recommendation for an exercise program prior to the first chemotherapy treatment.

• Breast cancer: percentage of patients with a documented assessment for chemotherapy-induced nausea and vomiting prior to the second round of moderately or highly emetogenic chemotherapy treatment.

• Breast cancer: percentage of patients with a documented assessment for distress, fatigue and sleep-wake disturbance after breast cancer diagnosis and prior to the first chemotherapy treatment.

• Breast cancer: percentage of patients with a documented intervention for psychosocial distress score of 4 or greater on the NCCN Distress Thermometer or moderate or greater psychosocial distress via any other validated tool or narrative note at any visit.

• Breast cancer: percentage of patients with a documented intervention for sleep-wake disturbance of 4 or greater on the PROMIS scale, or moderate or greater sleep-wake disturbance determined via any tool or narrative note at any visit.

• Breast cancer: percentage of patients with a documented re-assessment for distress, fatigue and sleep-wake disturbance at least one time each chemotherapy cycle.

• Breast cancer: percentage of patients with at least one documented assessment during the 12-month period after completing the final component of the treatment plan for each of the following: fatigue, pain, psychosocial distress, sleep; assessment for bone health risk, lymphedema, menopausal symptoms, or neuropathy as applicable to the patient based on the types of treatments received.

• Breast cancer: percentage of patients with at least one documented intervention to manage significant levels of symptoms for bone health risk, fatigue, lymphedema, menopausal symptoms, neuropathy, pain, psychosocial distress and sleep.

• Breast cancer: percentage of patients with at least one goal for the post-treatment period documented based on a patient identified topic that was established collaboratively between the patient and the healthcare team, shortly before the final treatment date or in the survivorship time period.

• Breast cancer: percentage of patients with documented education on neutropenia precautions prior to or at the time of the first chemotherapy administration.

• Breast cancer: percentage of patients with documented education or reinforcement of prior education on community resources, diet, exercise, late effects, and signs and symptoms of recurrence; documented education on lymphedema as applicable to the patient based on the treatments received.